Beyond Biotech - the podcast from Labiotech

Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

  1. 2d ago

    The ADC patent cliff: a turning point for rare cancer treatment

    Antibody-drug conjugates are one of the hottest areas in oncology. They pair the precision of an antibody with a potent drug payload, and the data keeps getting stronger. ESMO 2026 brought another wave of promising readouts. But could ADCs do more than add new options for common cancers? Could they let doctors target the molecular makeup of each patient’s tumour, whatever type of cancer it is? That’s the promise. The reality is more complicated. High development costs, crowded patent landscapes and limited tumour profiling all push developers towards the largest patient groups. That leaves people with rarer cancers behind. My guest today is Robert Andrews, Partner and Patent Attorney at Mewburn Ellis. Robert has spent more than 20 years advising ADC companies on patent strategy. We talk about where the field is heading, what patent expiries could unlock, and what needs to change for ADCs to deliver truly personalised cancer care. 01:28 Meet Robert Andrews 06:18 How ADCs could shift cancer treatment towards molecular profiling 09:45 ADC highlights from ESMO 2026 and China’s rise 15:00 Development costs, rare cancers and layered ADC patents 24:04 Patent expiries, biosimilar ADCs and the UPC 31:24 The next decade of ADCs and lessons from Korea Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Eight biotech companies spearheading the antibody drug conjugate new waveHarnessing antibody-drug conjugates (ADCs) in oncology: Pathways to clinical successTwice the punch: The emergence of dual-payload antibody and peptide drug conjugates

  2. Nov 13

    Inside Arbor’s CNS pipeline and next-generation gene editing

    Gene editing has spent the last decade proving what's possible in the lab. The next decade is about proving it can reach the patients who need it most, from ultra-rare liver diseases to conditions like ALS, where no truly effective treatments exist today.  Arbor Biotechnologies is one of the companies pushing that frontier, built on a diverse toolbox of editing technologies that goes beyond the limitations of first-generation CRISPR tools. Its lead clinical program, ABO-101, targets PH1, and last October the company struck a partnership with Chiesi Group worth up to two billion dollars in milestones, with European regulators granting the program orphan drug designation just this summer.  Arbor is also building out a CNS pipeline focused initially on ALS. Here to talk through the science, the strategy, and what's next is Devyn Smith, CEO of Arbor Biotechnologies. 01:36 – Meet Devyn Smith 07:48 – Arbor's toolbox approach versus single-editor CRISPR companies 12:16 – What PH1 is and how ABO-101 works 15:19 – Inside the Chiesi partnership for ABO-101 20:14 – Why ALS anchors Arbor's CNS pipeline 26:48 – Arbor's three-year outlook and long-term vision Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  What’s on the horizon for gene editing-based therapies?CRISPR technology’s next wave: Ten companies to watch in 2025 Beyond CRISPR: What CAST could bring to genome editing

  3. Oct 30

    Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)

    Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure. So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment. In part three of our series and ahead of Diabetes Awareness Month, I spoke with Ryan Confer, President and CEO of Genprex, about the company’s move from cancer into diabetes, the realities of making gene therapies at scale, and where a potential one-time treatment could fit alongside GLP-1s. 02:21 Meet Ryan Confer and Genprex09:49 What gene therapy can offer patients that GLP-1s cannot12:36 How GPX-002 works and the type 2 diabetes data presented at ASGCT17:22 Working with a CDMO to manufacture an AAV gene therapy at scale20:07 Standing out from GLP-1s and stem cell approaches in diabetes27:59 Diabetes Awareness Month and the prospect of a functional cureInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  The Metabolic Moment: 3 big bets to watch in metabolic diseaseBeyond GLP-1s: is there a new wave of metabolic disease treatments?The future of diabetes treatment: Is a cure possible?

    Genprex bets on a one-time gene therapy for diabetes (Part 3 of 3)
  4. Oct 23

    GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)

    Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure. So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment. In part two of our series,  I’m joined by Paul Little, CEO of Atrogi. We talk about what GLP-1s leave unsolved, the science behind ATR-258, and how a small company competes in a market led by giants. 02:24 Meet Paul Little05:08 What GLP-1s leave unsolved, from muscle loss to weight rebound10:29 How ATR-258 tunes beta-2 signalling to mimic exercise16:11 Avoiding the cardiovascular side effects of older beta-2 agonists19:03 What the new muscle power and body composition data mean22:03 Phase 2 options, oral advantages and the path to partneringInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  The Metabolic Moment: 3 big bets to watch in metabolic diseaseBeyond Ozempic: the GLP-1 landscape in 2026 What can GLP-1s do beside treat diabetes and obesity?

    GLP-1 muscle loss: the next battleground in obesity treatment (Part 2 of 3)
  5. Oct 16

    The next big shake-up in the GLP-1 market? (Part 1 of 3)

    Welcome to a special three-part series called 'The Metabolic Moment'. In just a few years, GLP-1 drugs have become a phenomenon. They’ve transformed how we treat diabetes and obesity, created one of the biggest markets in pharma, and sparked a cultural conversation that reaches far beyond the clinic. Now that market is shifting. Cheaper alternatives are coming, new mechanisms are entering trials, and some companies are aiming for something closer to a cure. So what happens next for patients, for the companies leading the field, and for the startups hoping to overtake them? Across three conversations, we’ll follow the money, the science, and the people behind this metabolic moment. In part one of our series,  I’m joined by Valeriia Simanovskaia, founder and CEO of BioBrokers, an independent capital markets and strategic advisory firm for life sciences. Trained at Harvard Medical School and based in Paris, Valeriia tracks where the money in biotech is flowing. 02:15 Meet Valeriia and BioBrokers09:07 Discontinuation rates and what they mean for GLP-1 sales12:39 Generic semaglutide arrives in India and Canada16:28 Why oral GLP-1s may become a separate market segment22:15 Amgen’s MariTide and the case for monthly dosing32:00 Why weight maintenance is the next competitive frontierInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  The Metabolic Moment: 3 big bets to watch in metabolic diseaseBeyond Ozempic: the GLP-1 landscape in 2026 Nine biotech companies that could revolutionize obesity treatments

    The next big shake-up in the GLP-1 market? (Part 1 of 3)
  6. Oct 9

    Saudi Arabia's biotech momentum: inside RGMBS 2026

    Saudi Arabia has spent the last four years building one of the most ambitious biotech gatherings in the region: the Riyadh Global Medical Biotechnology Summit. This September, the fourth edition brought together delegations from more than 57 countries and over 200 speakers, closing with more than 40 agreements and initiatives worth over SAR5 billion. From gene editing and genomics to AI-driven drug discovery and biomanufacturing, the Summit is positioning itself as a serious node in the global biotech map — and it's timed deliberately, arriving just weeks before BIO-Europe in Cologne. To unpack what happened in Riyadh, what it means for Saudi Arabia's biotech ambitions, and how the Summit connects to the conversations happening at BIO-Europe, I'm joined by Abdulaziz Aldayel, a nanomedicine researcher at the King Abdullah International Medical Research Center.  01:20 – Meet Abdulaziz Aldayel07:21 – What RGMBS has set out to achieve since 202111:44 – RGMBS dealmaking jumps to $1.3 billion21:17 – How RGMBS and BIO-Europe complement each other28:14 – What to expect at the next RGMBSThis episode is presented with the support of RGMBS. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Genomes to bioreactors: Saudi Arabia’s gene editing oncology pushSaudi Arabia: is the country set to become a global biotech hub?Saudi Arabia to inject $3B into vaccines and medicines industry

  7. Oct 2

    How Flagship's Valo is reshaping AI drug discovery with human data

    AI has been one of the biggest buzzwords in biotech for years now — but for all the technological progress, actual R&D productivity gains have been hard to find, and the cost of developing a new drug keeps climbing. My guest today believes that's because AI alone was never going to be the answer. Valo, a biotech founded by Flagship Pioneering, is betting on a different approach: combining AI, predictive chemistry, and — crucially — real-world human data from the very start of drug discovery, using access to more than 17 million longitudinal patient records, some spanning 20 years. That approach has already attracted major partners, including a Parkinson's collaboration with EMD Serono worth up to $3 billion and a cardiometabolic disease partnership with Novo.  Joining me to talk about it is Valo's CEO, Brian Alexander — a former practicing radiation oncologist whose years treating patients with aggressive brain tumors helped shape his mission to reimagine how we discover medicines. Brian, welcome to the show. 01:30 — Meet Brian Alexander04:17 — How treating brain tumor patients shaped his mission09:58 — Valo's two-platform approach to drug discovery16:23 — What 20-year patient records reveal about disease22:23 — Why Valo positions itself as pharma's R&D engine32:43 — How this approach could raise clinical success ratesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter To dive deeper into the topic:  Episode 198: The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human dataHow human-first datasets are reshaping AI drug discoveryWebinar: How AI has changed drug discovery & development, and what’s coming next

Ratings & Reviews

3.8
out of 5
4 Ratings

About

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

You Might Also Like